Teva in US agrees to 2017 for Vytorin generic, as Merck has other pending cases
This article was originally published in Scrip
Executive Summary
Teva Pharmaceutical Industries has settled patent infringement lawsuits brought by Merck & Co and will not bring a generic version of the hypolipidaemics Vytorin and Zetia to the US market until 25 April 2017, according to court documents. In the negotiated settlement, the full terms of which were not disclosed, Teva will not to make, sell or distribute any product until that time.